CANN GROUP LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.062 AUD | -1.59% |
|
-.--% | -36.08% |
| May. 07 | Cann Group Secures AU$5 Million Debt Facility | MT |
| Mar. 22 | Cann Group Secures Final Payment for Sale of Southern Facility | MT |
Presenter SpeechMatthew Wright (Attendees)[Operator Instructions] Presenting on behalf of Cann...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Cann Group Limited is an Australia-based company that is focused on developing, producing, and supplying innovative cannabis medicines. The principal activities of the Company include the cultivation of medicinal cannabis for both medicinal and research purposes pursuant to the licenses and permits issued to the group, the development and manufacture (via third party arrangements) of finished product formulations, and the pursuit and execution of various supply agreements with third parties. The Company supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. It also owns Satipharm and its patent-protected capsule technology. The Company's research, cultivation and good manufacturing practices (GMP) manufacturing facilities are located in Melbourne, and a cultivation and GMP manufacturing facility is near Mildura, Victoria.
Calendar
2024-08-25
- Q4 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -36.08% | 17.97M | |
| -.--% | 339M | |
| +40.21% | 289M | |
| +42.80% | 280M | |
| +44.19% | 188M | |
| +148.97% | 146M | |
| +49.96% | 136M | |
| -37.59% | 129M | |
| -28.57% | 121M | |
| +11.54% | 97.22M |
- Stock Market
- Equities
- CAN Stock
- News Cann Group Limited
- Transcript : Cann Group Limited, H1 2022 Earnings Call, Feb 18, 2022
